Lansberg Maarten G, Thijs Vincent N, Bammer Roland, Olivot Jean-Marc, Marks Michael P, Wechsler Lawrence R, Kemp Stephanie, Albers Gregory W
Stanford Stroke Center, 701 Welch Road, Suite B325, Palo Alto, CA 94304-9705, USA.
Stroke. 2008 Sep;39(9):2491-6. doi: 10.1161/STROKEAHA.107.508572. Epub 2008 Jul 17.
The aim of this exploratory analysis was to evaluate if a combination of MR angiography (MRA) and diffusion-weighted imaging (DWI) selection criteria can be used to identify patients with acute stroke who are likely to benefit from early reperfusion.
Data from DEFUSE, a study of 74 patients with stroke who received intravenous tissue plasminogen activator in the 3- to 6-hour time window and underwent MRIs before and approximately 4 hours after treatment were analyzed. The MRA-DWI mismatch model was defined as (1) a DWI lesion volume less than 25 mL in patients with a proximal vessel occlusion; or (2) a DWI lesion volume less than 15 mL in patients with proximal vessel stenosis or an abnormal finding of a distal vessel. Favorable clinical response was defined as an improvement on the National Institutes of Health Stroke Scale score of at least 8 points between baseline and 30 days or a National Institutes of Health Stroke Scale score </=1 at 30 days.
Twenty-seven of 62 patients (44%) had an MRA-DWI mismatch. There was a differential response to early reperfusion based on MRA-DWI mismatch status. Reperfusion was associated with an increased rate of a favorable clinical response in patients with an MRA-DWI mismatch (OR, 12.5; 95% CI, 1.8 to 83.9) and a lower rate in patients without mismatch (OR, 0.2; 95% CI, 0.0 to 0.8).
The MRA-DWI mismatch model appears to identify patients with stroke who are likely to benefit from reperfusion therapy administered in the 3- to 6-hour time window after symptom onset. The criteria established for the MRA-DWI mismatch model in this study require validation in an independent cohort.
本探索性分析旨在评估磁共振血管造影(MRA)和弥散加权成像(DWI)选择标准的组合是否可用于识别可能从早期再灌注中获益的急性卒中患者。
对DEFUSE研究的数据进行分析,该研究纳入了74例卒中患者,这些患者在3至6小时时间窗内接受了静脉注射组织纤溶酶原激活剂,并在治疗前及治疗后约4小时接受了MRI检查。MRA-DWI不匹配模型定义为:(1)近端血管闭塞患者的DWI病变体积小于25 mL;或(2)近端血管狭窄或远端血管有异常发现的患者的DWI病变体积小于15 mL。良好的临床反应定义为美国国立卫生研究院卒中量表(NIHSS)评分在基线和30天之间至少改善8分,或30天时NIHSS评分≤1分。
62例患者中有27例(44%)存在MRA-DWI不匹配。根据MRA-DWI不匹配状态,对早期再灌注有不同反应。再灌注与MRA-DWI不匹配患者良好临床反应率增加相关(OR,12.5;95%CI,1.8至83.9),与无不匹配患者的较低率相关(OR,0.2;95%CI,0.0至0.8)。
MRA-DWI不匹配模型似乎可识别出可能从症状发作后3至6小时时间窗内给予的再灌注治疗中获益的卒中患者。本研究中为MRA-DWI不匹配模型建立的标准需要在独立队列中进行验证。